Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

Background: Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated wi...

Full description

Bibliographic Details
Main Authors: Bruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, Giovanni Grignani, Elena Fumagalli, Silvia Gasperoni, Lorenzo D’Ambrosio, Lorena Incorvaia, Marco Stellato, Mariella Spalato Ceruso, Andrea Napolitano, Sergio Valeri, Daniele Santini, Giuseppe Tonini, Paolo Giovanni Casali, Angelo Paolo Dei Tos, Maria Abbondanza Pantaleo
Format: Article
Language:English
Published: SAGE Publishing 2018-08-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835918794623

Internet

https://doi.org/10.1177/1758835918794623

Similar Items